letrozole + human menopausal gonadotropin

Letrozole + human menopausal gonadotropin is a combination therapy used primarily for ovulation induction and ovarian stimulation in women with infertility, including those with polycystic ovary syndrome (PCOS) or unexplained/mild male-factor infertility. Letrozole is a non-steroidal aromatase inhibitor that reduces estrogen synthesis by inhibiting the enzyme aromatase (CYP19A1), leading to increased secretion of endogenous gonadotropins and enhanced follicular development. Human menopausal gonadotropin (HMG) contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH), directly stimulating the ovaries to promote follicular growth and maturation. The combination protocol has been shown to improve ovulation rates, endometrial thickness, clinical pregnancy rates, and live birth rates compared to monotherapy with either agent alone[2][4][6]. This regimen is commonly used in intrauterine insemination (IUI) cycles as well as for patients resistant to clomiphene citrate.

Other names

letrozole + HMG